SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
The public's lack of understanding regarding nicotine's biological effects frequently results in inaccurate claims disseminated by the media and general public. In some anti-smoking literature, the harm that tobacco smoking and nicotine addiction does is personified as Nick O'Teen, represented as a humanoid with some aspect of a cigarette or cigarette butt about him or his clothes and hat. Nick O'Teen was a villain that was created for the Health Education Council. The character was featured in three animated anti-smoking public service announcements in which he tries to get kids addicted to cigarettes before being foiled by the DC Comics character Superman. Nicotine was often compared to caffeine in advertisements in the 1980s by the tobacco industry, and later in the 2010s by the electronic cigarettes industry, in an effort to reduce the stigmatization and the public perception of the risks associated with nicotine use.
Traumatic acid is a monounsaturated dicarboxylic acid that occurs naturally in plants. The compound was first isolated from wounded bean plants by American chemists James English Jr. and James Frederick Bonner and Dutch scientist Arie Jan Haagen-Smit in 1939. Traumatic acid is a potent wound healing agent in plants ("wound hormone") that stimulates cell division near a trauma site to form a protective callus and to heal the damaged tissue. It may also act as a growth hormone, especially in inferior plants (e.g. algae). Traumatic acid is biosynthesized in plants by non-enzymatic oxidation of traumatin (12-oxo-trans-10-dodecenoic acid), another wound hormone. Traumatic acid, was among the first biologically active molecules isolated from plant tissues. This dicarboxylic acid was shown to be a potent wound healing agent in plant that stimulates cell division near a wound site, it derives from 18:2 or 18:3 fatty acid hydroperoxides after conversion into oxo- fatty acids. At normal conditions, traumatic acid is a solid, crystalline, water-insoluble substance. The salts and esters of traumatic acid are called traumatates. Traumatic acid is used as an intermediate in prostaglandin synthesis. It is also a constituent of some pharmaceutical products, such as the odontostomatologic gel Restomyl, due to its mucosal re-epithelialization activity.
Bacillus cereus Escherichia coli, other virulence properties, such as enteroinvasive (EIEC), enteropathogenic (EPEC), enterotoxigenic (ETEC), enteroaggregative (EAEC or EAgEC) Listeria monocytogenes Shigella spp. Staphylococcus aureus Streptococcus Vibrio cholerae, including O1 and non-O1 Vibrio parahaemolyticus Vibrio vulnificus Yersinia enterocolitica and Yersinia pseudotuberculosis Less common bacterial agents:
Sources: en.wikipedia.org
synonymous mutation Also synonymous substitution or samesense mutation. A type of mutation in which the substitution of one nucleotide base for another results, after transcription and translation, in an amino acid sequence which is identical to the original unmutated sequence. This is possible because of the degeneracy of the genetic code, which allows different codons to code for the same amino acid. Though synonymous mutations are often considered silent, this is not always the case; a synonymous mutation may affect the efficiency or accuracy of transcription, splicing, translation, or any other process by which genes are expressed, and thus become effectively non-silent. Contrast nonsynonymous mutation.
== Purification == Synthesized carbon nanotubes typically contain impurities and most importantly different chiralities of carbon nanotubes. Therefore, multiple methods have been developed to purify them including polymer-assisted, density gradient ultracentrifugation (DGU), chromatography and aqueous two-phase extraction (ATPE). These methods have been reviewed in multiple articles. Certain polymers selectively disperse or wrap CNTs of a particular chirality, metallic character or diameter. For example, poly(phenylenevinylenes) disperse CNTs of specific diameters (0.75–0.84 nm) and polyfluorenes are highly selective for semiconducting CNTs. Separation involves mainly two steps: sonicate the mixture (CNTs and polymers in solvent), then centrifuge. The supernatant will contain the desired CNTs. Density gradient ultracentrifugation is based on the density difference of CNTs, so that different components are layered in centrifuge tubes under centrifugal force. Chromatography-based methods include size exclusion (SEC), ion-exchange (IEX) and gel chromatography. For SEC, CNTs are separated due to the difference in size using a stationary phase with different pore size. As for IEX, the separation is achieved based on their differential adsorption and desorption onto chemically functionalized resins packed in an IEX column, so understanding the interaction between CNTs mixtures and resins is important. The first IEX was reported to separate DNA-SWCNTs. Gel chromatography is based on the partition of CNTs between stationary and mobile phase.
== A == abietadiene hydroxylase - acido-1 RNA motif -acrylamide gels - act 1 adaptor protein - actino-ugpB RNA motif - actinomyces-1 RNA motif - adenine - adenosine deaminase deficiency - adenovirus - adenylyl-(glutamate—ammonia ligase) hydrolase - agarose gel electrophoresis - agarose gel - akaryocyte - Alagille syndrome - alkaline lysis - allele - amino acids - amino terminus - amp resistance - amplification - amplicon - anchor sequence - animal model - anneal - anti-sense strand - antibiotic resistance - antibody - antisense - antisense strand - AP-1 site - apo-beta-carotenoid-14',13'-dioxygenase - apoptosis - apovitellenin-1 - archease - arenicin - ArgJ protein family - ascorbate 2,3-dioxygenase - assembled epitope - ataxia-telangiectasia - ATG or AUG - ATP cone - Atrial septal defect 1 - autoimmune lymphoproliferative syndrome - autoradiography - autosomal dominant - autosome - avidin -
In November, Kennedy signed the act and issued an Executive Order tasking the Secretary of State to create, within the State Department, the "Agency for International Development" (or A.I.D.: subsequently re-branded as USAID), as the successor to both ICA and the Development Loan Fund. With these actions, the U.S. created a permanent agency working with administrative autonomy under the policy guidance of the State Department to implement, through resident field missions, a global program of both technical and financial development assistance for low-income countries. This structure has continued to date. Taking this momentum onto the world stage via an address to the UN General Assembly in September 1961, Kennedy called for a "United Nations Decade of Development". This initiative was endorsed by a General Assembly resolution in December, establishing the concepts of development and development assistance as global priorities.
Sources: en.wikipedia.org
=== Procedures === More advanced cases may be resistant or unresponsive to medical therapy and require hair transplantation. Naturally occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in proximity and in large numbers. The grafts are obtained from either follicular unit transplantation (FUT) or follicular unit extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts, and in the latter, individual hairs are extracted manually or robotically. The surgeon then implants the grafts into small incisions, called recipient sites. Cosmetic scalp tattoos can also mimic the appearance of a short, buzzed haircut.
=== EC 1.17.4 With a disulfide as acceptor === EC 1.17.4.1: ribonucleoside-diphosphate reductase EC 1.17.4.2: ribonucleoside-triphosphate reductase (thioredoxin) EC 1.17.4.3: transferred to EC 1.17.7.1, (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase. EC 1.17.4.4: vitamin-K-epoxide reductase (warfarin-sensitive) EC 1.17.4.5: vitamin-K-epoxide reductase (warfarin-insensitive)
S: Skin. The skin of the scalp contains numerous hair follicles and sebaceous glands. C: Connective tissue. A dense subcutaneous layer of fat and fibrous tissue that lies beneath the skin, containing the nerves and vessels of the scalp. A: Aponeurosis. The epicranial aponeurosis or galea aponeurotica is a tough layer of dense fibrous tissue which anchors the above layers in place. It runs from the frontalis muscle anteriorly to the occipitalis posteriorly. L: Loose areolar connective tissue. This layer has a gel-like consistency, and allows the more superficial layers of the scalp to shift about in relation to the pericranium. It is constituted of more matrix than fibers. It contains random collagen I bundles, collagen III and is rich in glycosaminoglycans (GAGs). In craniofacial surgery and neurosurgery this layer provides an easy plane of separation between the upper three layers and the pericranium. In scalping the scalp is also torn off through this layer. The layer is sometimes referred to as the "danger zone" because infectious agents can easily spread through it to emissary veins which drain into the cranium. P: Pericranium. This is the periosteum of the skull bones, a membrane that provides nutrition to the bone and the capacity for repair. During surgery it can be lifted from the bone to allow the removal of windows of bone (craniotomy).
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.